Wouter Joustra - 16 Jun 2026 Form 4 Insider Report for enGene Therapeutics Inc. (ENGN)

Reporting relationship: Director
Issuer ticker: ENGN
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 17:37:15 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Lee Giguere, as attorney-in-fact for the Reporting Person

Key filing fact

Wouter Joustra filed Form 4 for enGene Therapeutics Inc. (ENGN) on 17 Jun 2026.

Key facts

This page summarizes Wouter Joustra's Form 4 filing for enGene Therapeutics Inc. (ENGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 17:37.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001897813 Primary reporting owner

Joustra Wouter

Relationship: Director
Address: C/O 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA
Signature: /s/ Lee Giguere, as attorney-in-fact for the Reporting Person
Signature date: 17 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +31,000
Change %
Price: $0.000000^*
Shares after: 31,000
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 31,000
Exercise price: $1.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.